Calgary, Alberta | July 29, 2020 - Syantra Inc., a privately-held healthcare company today announced its amalgamation with Sy Diagnostics and KRS Biopharma. The three companies have consolidated as Syantra Inc. and are leveraging the collective strength of their intellectual property and the synergies of their research and product development for diagnostics and therapeutics.
“The combined company allows us to be more powerful in our approach, especially with regard to data and outcomes” said Robert Shepherd, Syantra Inc. president and CEO. “This amalgamation brings together our diagnostic platform, including our blood-based breast cancer detection test, with KRS Biopharma’s patented technologies, enabling us to create more specific therapies.”
“This is the ideal next step for Syantra Inc. The addition of KRS Biopharma allows us to move quickly into precision medicine. We can now address both early detection of disease and targeted treatment,” said Shepherd.
About KRS Biopharma and Cy Diagnostics
KRS Biopharma was a Calgary-based corporation focussed on creating targeted therapeutics through a patented platform approach. When combined with clinical data and artificial intelligence, KRS developed a path to establish novel modes of disease and evaluation of drug intervention.
Sy Diagnostics was the Calgary based precursor to Syantra Inc.. The consolidation of Sy Diagnostics and Syantra Inc. simplifies Syantra’s management, operations and reporting as related to cancer diagnostics.
Management and organization
Effective on the amalgamation, Robert Shepherd remains president and chief executive officer of the combined Syantra Inc. Senior leadership includes Kristina Rinker, PhD, PEng, as co-founder and chief scientific officer, Kenneth Fuh, PhD, MLT, as co-founder and development scientist, and Michelle Nanjad as vice president of Operations.
Additionally, effective upon amalgamation, the Board of Directors includes Mr. Shepherd and Dr. Rinker, as well as an additional director from KRS Biopharma: vascular surgeon Randy Moore, MD. The team is rounded out by two previous Syantra Inc. Board members: Peter Calverley, former CEO, COOL-IT; CFO, Tela Innovations (Calgary and USA) and Alice Reimer, former CEO of Chaordix and Evoco, serial entrepreneur (Calgary); and US based Rifat Pamukcu, MD, CEO Midway Pharmaceuticals, serial pharma/biotech entrepreneur.
